Inhibition of angiogenesis in disease states with an anti-αvβ3 monoclonal antibody
AssigneeThe Scripps Research Institute
InventorsPeter Brooks, David A. Cheresh
Life of this patent
Estimating the term…
Abstract
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3 antagonists.
Claims63
A method of inducing tumor tissue regression in a patient comprising administering to said patient a therapeutically effective amount of an antibody immunospecific for αvβ3.
A method of inducing solid tumor tissue regression in a human patient in need thereof, said method comprising administering to said human patient a therapeutically effective amount of a humanized monoclonal antibody immunospecific for αvβ3 complex.
Dependencies are inferred from the claim text.